Male predominant association with Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G variants (rs6001417, rs35228531, rs8177832) predict protection against HIV-1 infection

Qaisar Ali, Arshad Jamal, Sajjad Ullah, Ahmed Bilal Waqar


Background: Human immunodeficiency virus (HIV) infection, it is a global health concern mainly lead to acquired immune deficiency syndrome (AIDS). There are numerous limitations of this infection particularly in the form of host factors which may limit and interfere HIV-1 replication. The most notable host factors which hinder HIV-1 DNA propagation is the apolipoprotein B mRNA-editing enzyme, catalytic polypeptide- like 3G (APOBEC3G). Any genetic polymorphism of this substantial host factor may impact the host susceptibility pattern to HIV viral infection in different part of the world. The aim of this study to examine genetic variants (rs6001417, rs35228531, rs8177832) effecting HIV-1 infection.

Method: Three variants of APOBEC3G gene polymorphism were genotyped while using RT-PCR method. Frequency distribution of these genotypes was evaluated in both the HIV-1 and healthy group.

Results: The rs6001417 CG (p = 0.03) and rs35228531 CT (p = 0.01) genotypes were found as protective elements, while rs35228531 TT (p = 0.02) and rs8177832 AA (p = 0.03) genotypes had shown susceptibility against the HIV-1 infection. Our data suggest, rs35228531 CT (p = 0.003) and rs8177832 AA (P = <0.001) genotypes have predominant incidences in HIV-1 male population than healthy control.

Conclusion: We predict rs6001417 CG, rs35228531 CT as protective and rs35228531 TT, rs8177832 AA genotypes as a predisposing tool, against the HIV-1 infection in a section of Pakistani population. In addition, male gender was found predominantly high in both protective genotype rs35228531 CT (p = 0.003) and predisposing genotype rs8177832 AA (p = <0.001). The predominant contribution may help the patient to be predict about the status of HIV infection, however, extra efforts are required to study larger cohort of patients to better elucidate the association.

Full Text:



Barré-Sinoussi F, Chermann J-C, Rey F, Nugeyre MT, Chamaret S, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science, (1983); 220(4599): 868-871.

Tang JW, Chan PK. The basics of HIV medicine. SS Lee, JCY, (2007).

Murray CJ, Ortblad KF, Guinovart C, Lim SS, Wolock TM, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet, (2014); 384(9947): 1005-1070.

Kharsany AB, Karim QA. HIV infection and AIDS in Sub-Saharan Africa: current status, challenges and opportunities. The open AIDS journal, (2016); 1034.

Imran M, Manzoor S, Saalim M, Resham S, Ashraf J, et al. HIV‐1 and hijacking of the host immune system: the current scenario. Apmis, (2016); 124(10): 817-831.

Oberle CS, Joos B, Rusert P, Campbell NK, Beauparlant D, et al. Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs. Retrovirology, (2016); 13(1): 62.

An P, Bleiber G, Duggal P, Nelson G, May M, et al. APOBEC3G genetic variants and their influence on the progression to AIDS. Journal of virology, (2004); 78(20): 11070-11076.

An P, Penugonda S, Thorball CW, Bartha I, Goedert JJ, et al. Role of APOBEC3F gene variation in HIV-1 disease progression and pneumocystis pneumonia. PLoS genetics, (2016); 12(3): e1005921.

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nature immunology, (2002); 3(11): 991.

van Kooyk Y, Appelmelk B, Geijtenbeek TB. A fatal attraction: Mycobacterium tuberculosis and HIV-1 target DC-SIGN to escape immune surveillance. Trends in molecular medicine, (2003); 9(4): 153-159.

D'Urbano V, De EC, Re M. Host restriction factors and Human immunodeficiency Virus (HIV-1): a dynamic interplay involving all phases of the viral life cycle. Current HIV research, (2018).

Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology, (2003); 37(3): 493-503.

Janssen R, Bont L, Siezen CL, Hodemaekers HM, Ermers MJ, et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes. Journal of Infectious Diseases, (2007); 196(6): 826-834.

Powell EE, Edwards‐Smith CJ, Hay JL, Clouston AD, Crawford DH, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology, (2000); 31(4): 828-833.

Piacentini L, Biasin M, Fenizia C, Clerici M. Genetic correlates of protection against HIV infection: the ally within. J Intern Med, (2009); 265(1): 110-124.

A Estrada-Aguirre J, G Cazarez-Salazar S, A Ochoa-Ramirez L, de J Acosta-Cota S, Zamora-Gómez R, et al. Protective effect of CCR5 Delta-32 allele against HIV-1 in Mexican women. Current HIV research, (2013); 11(6): 506-510.

Kenny-Walsh E. The natural history of hepatitis C virus infection. Clinics in liver disease, (2001); 5(4): 969-977.

Dolo A, Modiano D, Maiga B, Daou M, Dolo G, et al. Difference in susceptibility to malaria between two sympatric ethnic groups in Mali. The American journal of tropical medicine and hygiene, (2005); 72(3): 243-248.

Perera FP. Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. JNCI: Journal of the National Cancer Institute, (1996); 88(8): 496-509.

Duggal NK, Emerman M. Evolutionary conflicts between viruses and restriction factors shape immunity. Nature Reviews Immunology, (2012); 12(10): 687.

Kagoné TS, Bisseye C, Méda N, Testa J, Pietra V, et al. A variant of DC-SIGN gene promoter associated with resistance to HIV-1 in serodiscordant couples in Burkina Faso. Asian Pacific journal of tropical medicine, (2014); 7S93-S96.

Harris RS, Liddament MT. Retroviral restriction by APOBEC proteins. Nature Reviews Immunology, (2004); 4(11): 868.

Merindol N, Berthoux L. Restriction factors in HIV-1 disease progression. Current HIV research, (2015); 13(6): 448-461.

Imran M, Manzoor S, Saalim M, Resham S, Ashraf J, et al. HIV-1 and hijacking of the host immune system: the current scenario. APMIS, (2016); 124(10): 817-831.

Ayinde D, Casartelli N, Schwartz O. Restricting HIV the SAMHD1 way: through nucleotide starvation. Nature Reviews Microbiology, (2012); 10(10): 675.

Ali Q, Jamal A, Imran M, Ullah S, Kalam I, et al. Correlation of IL28B rs12979860 genotype and gender with spontaneous clearance of HCV infection: a Pakistani cross-section study. Personalized medicine, (2018); 15(6).

Kadota K, Mori M, Yanagimachi M, Miyamae T, Hara T, et al. Analysis of gender differences in genetic risk: association of TNFAIP3 polymorphism with male childhood-onset systemic lupus erythematosus in the Japanese population. PLoS One, (2013); 8(8): e72551.

An P, Johnson R, Phair J, Kirk GD, Yu X-F, et al. APOBEC3B deletion and risk of HIV-1 acquisition. The Journal of infectious diseases, (2009); 200(7): 1054-1058.

Svarovskaia ES, Xu H, Mbisa JL, Barr R, Gorelick RJ, et al. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. Journal of Biological Chemistry, (2004); 279(34): 35822-35828.

Feng Y, Love RP, Chelico L. HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G. Journal of Biological Chemistry, (2013); 288(9): 6083-6094.

Iwabu Y, Kinomoto M, Tatsumi M, Fujita H, Shimura M, et al. Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes. Journal of Biological Chemistry, (2010); 285(46): 35350-35358.

Bishop KN, Holmes RK, Malim MH. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. Journal of virology, (2006); 80(17): 8450-8458.

Sheehy AM, Erthal J. APOBEC3 versus retroviruses, immunity versus invasion: clash of the titans. Molecular biology international, (2012); 2012.

Eller L, Manak M, Shutt A, Malia J, Trichavaroj R, et al. Performance of the Determine HIV 1/2 Ag/Ab Combo Rapid Test on Serial Samples from an Acute Infection Study (RV217) in East Africa and Thailand; 2013. MARY ANN LIEBERT, INC 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA. pp. A73-A74.

Suguna S, Nandal D, Kamble S, Bharatha A, Kunkulol R. Genomic DNA isolation from human whole blood samples by non enzymatic salting out method. Int J pharm pharm sci, (2014); 6198-199.

Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science, (1996); 273(5283): 1856-1862.

McNab F, Mayer-Barber K, Sher A, Wack A, O'garra A. Type I interferons in infectious disease. Nature Reviews Immunology, (2015); 15(2): 87.

An P, Bleiber G, Duggal P, Nelson G, May M, et al. APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol, (2004); 78(20): 11070-11076.

Do H, Vasilescu A, Diop G, Hirtzig T, Heath SC, et al. Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. J Infect Dis, (2005); 191(2): 159-163.

Nadembega W, Giannella S, Simporé J, Ceccherini‐Silberstein F, Pietra V, et al. Characterization of drug‐resistance mutations in HIV‐1 isolates from non‐HAART and HAART treated patients in Burkina Faso. Journal of medical virology, (2006); 78(11): 1385-1391.

Saeed MA, Ahmed N, Ali Q. Frequency of Autoantibodies to Thyroid Peroxidase (TPO) in Patients with Type 1 Diabetes Mellitus. (2018).

Compaore TR, Soubeiga ST, Ouattara AK, Obiri-Yeboah D, Tchelougou D, et al. APOBEC3G Variants and Protection against HIV-1 Infection in Burkina Faso. PloS one, (2016); 11(1).

Do H, Vasilescu A, Diop G, Hirtzig T, Heath SC, et al. Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. Journal of Infectious Diseases, (2005); 191(2): 159-163.

Iqbal K, Imran M, Ullah S, Jamal M, Waheed Y, et al. Correlation of apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G genetic variant rs8177832 with HIV-1 predisposition in Pakistani population. Current HIV research, (2018); 16(4): 297-301.

De Maio FA, Rocco CA, Aulicino PC, Bologna R, Mangano A, et al. Effect of HIV-1 Vif variability on progression to pediatric AIDS and its association with APOBEC3G and CUL5 polymorphisms. Infection, Genetics and Evolution, (2011); 11(6): 1256-1262.

Ali Q, Kalam I, Ullah S, Jamal A, Imran M, et al. Predictive value of IL-28B rs12979860 variants for peg-IFN, sofosbuvir plus ribavirin treatment of HCV infection in Pakistani population. Personalized medicine, (2018); 15(6).

Kalam I, Ullah S, Ali Q, Jamal A, Waqar AB. Impact of IL28B gene variants (rs12979860) in peg-IFN therapy against Chronic Hepatitis B Pakistani patients. Advancements in Life Sciences, (2018); 6(1): 11-18.


  • There are currently no refbacks.